Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

OKYO Pharma Limited - Ordinary Shares (NQ:OKYO)

1.944 -0.246 (-11.23%)
Streaming Delayed Price Updated: 11:02 AM EST, Jan 29, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about OKYO Pharma Limited - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Announces Distinguished Ophthalmologists with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Join its Scientific Advisory Board
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Both Sign and Symptom Endpoints in its First-in-Human Phase 2 Trial of OK-101 in Patients with Dry Eye Disease
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma to Present at the Biotech Showcase Conference in San Francisco, January 8-10, 2024
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Announces Last Patient Enrolled in OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease Has Completed Final Protocol Visit
Top-line Efficacy and Safety Data on Track for Release in December 2023 
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Announces $5.84 Million Cash Raise and Payables Reduction
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
Dow Rebounds, Still Below Fair Value ↗
The Israeli-Palestinian conflict is in focus worldwide, after erupting into a deadly war over the weekend. 
Via Talk Markets
Topics Stocks
News headline image
OKYO Pharma Announces Filing of an Investigational New Drug (IND) Application for OK-101 to Treat Neuropathic Corneal Pain (“NCP”)
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Dry Eye Disease Affects Around 50M Americans, OKYO Pharma's Candidate Shows Safety In Mid-Stage Study ↗
OKYO Pharma Limited (NASDAQ: OKYO) announced that its first drug candidate, OK-101, presently in a 240-patient phase 2 trial in patients with dry eye disease (DED) is currently showing a positive... 
Via Benzinga
News headline image
OKYO Pharma Announces Positive Safety Data Profile for the ongoing OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease ("DED")
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
Why Accolade Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
Gainers Orchard Therapeutics plc (NASDAQ: ORTX) shares climbed 97.7% to $15.98 after the company agreed to be acquired by Japan's Kyowa Kirin for $16.00 per ADS in cash plus an additional contingent... 
Via Benzinga
OKYO Pharma’s Advancing Clinical Mission to Better Treat Eye Disease Sends Shares 89% Higher Since August ($OKYO)
Via AB Newswire
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
Why Nikola Shares Are Trading Higher By 33%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
Gainers 
Via Benzinga
News headline image
Why Rubicon Technologies Shares Are Trading Lower By Over 7%; Here Are 20 Stocks Moving Premarket ↗
Gainers T2 Biosystems, Inc. (NASDAQ: TTOO) shares rose 44.4% to $0.4003 in pre-market trading. T2 Biosystems said it issued inducement awards to four new employees. 
Via Benzinga
News headline image
Why Volcon Shares Are Trading Lower By 19%; Here Are 20 Stocks Moving Premarket ↗
Gainers AgriFORCE Growing Systems Ltd. (NASDAQ: AGRI) shares rose 38.7% to $0.1421 in pre-market trading after gaining 10% on Thursday. 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗
We're starting the final day of trading this week with a breakdown of the biggest pre-market stock movers for Friday morning! 
Via InvestorPlace
News headline image
OKYO Pharma Announces Closing of $4.0 Million Registered Direct Offering of Ordinary Shares
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
Why Clearmind Medicine Shares Are Trading Lower By 53%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers First Wave BioPharma, Inc. (NASDAQ: FWBI) shares jumped 89.5% to $0.8243 after the company announced license agreement for capeserod from Sanofi. 
Via Benzinga
News headline image
OKYO Pharma Announces Pricing of $4.0 Million Registered Direct Offering of Ordinary Shares
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Limited Announces Withdrawal of Public Offering
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
Why Novo Integrated Sciences Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket ↗
Gainers TransCode Therapeutics, Inc. (NASDAQ: RNAZ) shares rose 43.3% to $1.29 in pre-market trading. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.